evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 2 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Donepezil 23 mg/day vs donepezil 10 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Risk for at least one adverse event per patient · people with severe Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).

1 finding from 1 review